Table 1.
Patient demographics and clinical characteristics of uterine adenosarcoma, endometrial stromal sarcoma, and leiomyosarcoma (N = 9410).
| Characteristic | UAS |
ESS |
LMS |
P-value |
|---|---|---|---|---|
| n = 994 | n = 2910 | n = 5506 | ||
| Age (y) | 58.4 (±14.9) | 54.2 (±14.0) | 54.6 (±12.4) | <0.001 |
| ≥60 | 480 (48.3%) | 923 (31.7%) | 167 (30.3%) | |
| <60 | 514 (51.7%) | 1987 (68.3%) | 3835 (69.7%) | |
| Ethnicity | <0.001 | |||
| Caucasian | 652 (65.6%) | 1891 (65.0%) | 3410 (62.1%) | |
| African American | 131 (13.2%) | 394 (13.5%) | 950 (17.3%) | |
| Hispanic | 113 (11.4%) | 357 (12.3%) | 674 (12.2%) | |
| Asian | 70 (7.0%) | 214 (7.4%) | 362 (6.6%) | |
| Others | 28 (2.8%) | 54 (1.9%) | 100 (1.8%) | |
| Marital status | <0.001 | |||
| Single | 194 (19.5%) | 489 (16.8%) | 1020 (18.5%) | |
| Married | 488 (49.1%) | 1647 (56.6%) | 3080 (55.9%) | |
| Others | 312 (31.4%) | 774 (26.6%) | 1406 (25.5%) | |
| Registry Area | 0.014 | |||
| West | 525 (52.8%) | 1498 (51.5%) | 2849 (51.7%) | |
| Central | 193 (19.4%) | 708 (24.3%) | 1239 (22.5%) | |
| East | 276 (27.8%) | 704 (24.2%) | 1418 (25.8%) | |
| Year at diagnosis | <0.001 | |||
| 1973–1999 | 236 (23.7%) | 946 (32.5%) | 1979 (35.9%) | |
| 2000–2009 | 523 (52.6%) | 1383 (47.5%) | 2406 (43.7%) | |
| 2010–2013 | 235 (23.6%) | 581 (20.0%) | 1121 (20.4%) | |
| Stage | <0.001 | |||
| I | 560 (56.3%) | 1138 (39.1%) | 2024 (36.8%) | |
| II | 13 (1.3%) | 79 (2.7%) | 140 (2.5%) | |
| III | 33 (3.3%) | 226 (7.8%) | 241 (4.4%) | |
| IV | 51 (5.1%) | 620 (21.3%) | 1480 (26.9%) | |
| Unknown | 337 (33.9%) | 847 (29.1%) | 1621 (29.4%) | |
| Myometrial invasion | <0.001 | |||
| ≤50% | 393 (39.5%) | 663 (22.8%) | 883 (16.0%) | |
| >50% | 43 (4.3%) | 87 (3.0%) | 64 (1.2%) | |
| Unknown | 558 (56.1%) | 2160 (74.2%) | 4559 (82.8%) | |
| Lymph nodes metastasis | <0.001 | |||
| Negative | 848 (85.3%) | 2006 (68.9%) | 3561 (64.7%) | |
| Positive | 29 (2.9%) | 192 (6.6%) | 188 (3.4%) | |
| Unknown | 117 (11.8%) | 712 (24.5%) | 1757 (31.9%) | |
| Grade | <0.001 | |||
| 1 | 109 (11.0%) | 465 (16.0%) | 314 (5.7%) | |
| 2 | 158 (15.9%) | 926 (31.8%) | 573 (10.4%) | |
| 3a | 173 (17.4%) | 914 (31.4%) | 2003 (36.4%) | |
| Unknown | 554 (55.7%) | 605 (20.8%) | 2616 (47.5%) | |
| Tumor size | <0.001 | |||
| ≤2.0 cm | 82 (8.2%) | 183 (6.3%) | 145 (2.6%) | |
| 2.1–5.0 cm | 186 (19.7%) | 453 (15.6%) | 463 (8.4%) | |
| >5.0 cm | 318 (33.6%) | 1084 (37.2%) | 3096 (56.3%) | |
| Unknown | 408 (41.0%) | 1190 (40.9%) | 1802 (32.7%) | |
| Surgery type | <0.001 | |||
| No surgery | 46 (4.6%) | 293 (10.1%) | 466 (8.5%) | |
| Total/pan/simple hyst | 720 (72.4%) | 1848 (63.5%) | 3383 (61.4%) | |
| Others | 228 (22.9%) | 769 (26.4%) | 1657 (30.1%) | |
| Radiotherapy | <0.001 | |||
| No adjuvant radiation | 746 (75.1%) | 1850 (63.6%) | 3335 (60.6%) | |
| Adjuvant radiation | 171 (17.2%) | 493 (16.9%) | 871 (15.8%) | |
| Others | 77 (7.7%) | 567 (19.5%) | 1300 (23.6%) |
Number (%) or mean (±SD) is shown. One-way ANOVA or chi-square test for P-values. Significant P-values are emboldened.
Abbreviations: UAS, uterine adenosarcoma; ESS, endometrial stromal sarcoma; LMS, leiomyosarcoma; and hyst, hysterectomy.
a
Included undifferentiated type.